Big Pharma Earnings Spark Sector Rotation

Pfizer provided a rare bright spot for the industry, with shares climbing after second-quarter results surpassed Wall Street expectations. The New York-based firm successfully balanced a sharp downturn in Covid-19 product sales against robust growth in its oncology and cardiovascular drug portfolios. Conversely, Merck tempered investor enthusiasm by lowering its full-year profit guidance, a move necessitated by one-time costs associated with the acquisition of biotech firm Terns Pharmaceuticals. Despite the downward revision, Merck shares managed a modest gain.

The volatility extended to Europe, where Novo Nordisk saw its stock slide. The Danish manufacturer of weight-loss treatments faced a muted reaction from shareholders, even after the company hiked its revenue projections for the year. This tepid response underscores the current climate, where high expectations for growth are increasingly challenged by valuation concerns across the healthcare landscape.